An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure

Cardiology

Volumn 110, Issue 2, 2008, Pages 112-115

  Page II, Robert Lee ^a   Ferguson, Debra ^a   Cantu, Mona ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Heart failure; Helicobacter pylori; Levofloxacin

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; PENICILLIN G; SULFANILAMIDE;

ADULT; ANAMNESIS; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; FOLLOW UP; HEART FAILURE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; PRIORITY JOURNAL;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; HEART FAILURE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; PROTON PUMP INHIBITORS;

EID: 43049138468     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110489     Document Type: Article

References (18)

1. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG: Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006;6:699-709.
2. Cavallaro LG, Egan B, O'Morain C, Di Mario F: Treatment of Helicobacter pylori infection. Helicobacter 2006;11(suppl 1):36-39.
3. Di Bonaventura G, Piccolomini R, Pompilio A, Zappacosta R, Piccolomini M, Neri M: Serum and mucosal cytokine profiles in patients with active Helicobacter pylori and ischemic heart disease: is there a relationship? Int J Immunopathol Pharmacol 2007;20:163-172.
4. Collins J, Ali-Ibrahim A, Smoot DT: Antibiotic therapy for Helicobacter pylori. Med Clin North Am 2006;90:1125-1140.
5. Howden CW, Hunt RH: Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2330-2338.
6. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ: Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007;56:772-781.
7. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G: Current concepts in the management of Helicobacter pylori infection - the Maastricht 2 - 2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
8. Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, Thomson A, Bursey F, Blackshaw P, Frail D, Sinclair P: An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000;162:S3-S23.
9. Pepto-bismol® chewable tablets. http://www.pepto-bismol.com/tablets. shtml (accessed May 6, 2006).
10. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR: Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981;305:789-794.
11. Saad RJ, Schoenfeld P, Kim HM, Chey WD: Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-496.
12. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ, Cambau E: Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007;29:389-396.
13. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, Gasbarrini G: Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-1343.
14. Gisbert JP, Morena F: Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
15. Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS: Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006;11:46-51.
16. Sharara AI, Chaar HF, Racoubian E, Moukhachen O, Barada KA, Mourad FH, Araj GF: Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 2004;9:255-261.
17. Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ: Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000;46:283-285.
18. Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M, Santarelli L, Zocco MA, Ojetti V, Carloni E, Cammarota G, Gasbarrini G, Gasbarrini A: Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-633.